LTC3094353I2 - - Google Patents
Info
- Publication number
- LTC3094353I2 LTC3094353I2 LTPA2023514C LTPA2023514C LTC3094353I2 LT C3094353 I2 LTC3094353 I2 LT C3094353I2 LT PA2023514 C LTPA2023514 C LT PA2023514C LT PA2023514 C LTPA2023514 C LT PA2023514C LT C3094353 I2 LTC3094353 I2 LT C3094353I2
- Authority
- LT
- Lithuania
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461927819P | 2014-01-15 | 2014-01-15 | |
| PCT/US2015/011391 WO2015108967A2 (en) | 2014-01-15 | 2015-01-14 | Rsv-specific antibodies and functional parts thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LTPA2023514I1 LTPA2023514I1 (enExample) | 2023-05-25 |
| LTC3094353I2 true LTC3094353I2 (enExample) | 2025-07-10 |
Family
ID=53543612
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP15737068.5T LT3094353T (lt) | 2014-01-15 | 2015-01-14 | Rsv specifiški antikūnai ir jų funkcionalios dalys |
| LTPA2023514C LTC3094353I2 (enExample) | 2014-01-15 | 2023-04-28 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP15737068.5T LT3094353T (lt) | 2014-01-15 | 2015-01-14 | Rsv specifiški antikūnai ir jų funkcionalios dalys |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US20160340414A1 (enExample) |
| EP (3) | EP3094353B1 (enExample) |
| JP (3) | JP6836398B2 (enExample) |
| KR (1) | KR102188437B1 (enExample) |
| CN (2) | CN116355080A (enExample) |
| AU (4) | AU2015206570A1 (enExample) |
| CA (1) | CA2933200C (enExample) |
| CY (2) | CY1123425T1 (enExample) |
| DK (1) | DK3094353T3 (enExample) |
| ES (1) | ES2795727T3 (enExample) |
| FI (1) | FIC20230016I1 (enExample) |
| FR (1) | FR23C1016I2 (enExample) |
| HR (1) | HRP20200607T1 (enExample) |
| HU (2) | HUE048855T2 (enExample) |
| LT (2) | LT3094353T (enExample) |
| LU (1) | LUC00305I2 (enExample) |
| MX (1) | MX374517B (enExample) |
| NL (1) | NL301228I2 (enExample) |
| NO (1) | NO2023016I1 (enExample) |
| PL (1) | PL3094353T3 (enExample) |
| PT (1) | PT3094353T (enExample) |
| RS (1) | RS60387B1 (enExample) |
| SI (1) | SI3094353T1 (enExample) |
| SM (1) | SMT202000282T1 (enExample) |
| TW (1) | TWI705974B (enExample) |
| WO (1) | WO2015108967A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| RS60387B1 (sr) | 2014-01-15 | 2020-07-31 | Medimmune Llc | Rsv-specifična antitela i njihovi funkcionalni delovi |
| WO2018075954A2 (en) * | 2016-10-21 | 2018-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| TWI911431B (zh) * | 2017-03-01 | 2026-01-11 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| KR20200140799A (ko) * | 2018-01-31 | 2020-12-16 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | 호흡기 세포융합 바이러스에 대하여 사용하기 위한 핵산 항체 작제물 |
| CN111606993B (zh) * | 2019-02-26 | 2022-06-28 | 中国科学院上海生命科学研究院 | 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用 |
| US12024553B2 (en) | 2019-04-30 | 2024-07-02 | Medimmune Limited | Dosage regimens for and compositions including anti-RSV antibodies |
| KR20240055097A (ko) | 2021-09-13 | 2024-04-26 | 메디뮨 리미티드 | 니르세비맙을 사용한 호흡기 세포융합 바이러스 하기도 감염의 예방 |
| CN116987183B (zh) * | 2022-07-22 | 2024-10-15 | 北京智仁美博生物科技有限公司 | 抗呼吸道合胞病毒中和性抗体及其用途 |
| CN122057014A (zh) * | 2024-11-08 | 2026-05-19 | 珠海泰诺麦博制药股份有限公司 | 一种抗rsv抗体在预防和治疗rsv中的应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| CA2585891A1 (en) * | 2004-10-29 | 2006-05-11 | Medimmune, Inc. | Methods of preventing and treating rsv infections and related conditions |
| AU2005335714B2 (en) * | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| SI2066351T1 (sl) | 2006-10-02 | 2016-02-29 | E.R. Squibb & Sons, L.L.C. | Humana protitelesa, ki vežejo cxcr4 in njihova uporaba |
| CA2678628A1 (en) | 2007-03-06 | 2008-09-12 | Symphogen A/S | Recombinant antibodies for treatment of respiratory syncytial virus infections |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| US20110008329A1 (en) * | 2007-06-26 | 2011-01-13 | Medlmmune, Llc | Methods of Treating RSV Infections And Related Conditions |
| US8092804B2 (en) * | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| ES2579231T3 (es) | 2008-01-15 | 2016-08-08 | Abbvie Inc | Vectores de expresión de mamíferos mejorados y usos de los mismos |
| WO2011008093A1 (en) * | 2009-07-15 | 2011-01-20 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
| MX2012001882A (es) * | 2009-08-13 | 2012-04-11 | Crucell Holland Bv | Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso. |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| WO2011043643A1 (en) * | 2009-10-06 | 2011-04-14 | Medimmune Ltd | Rsv-specific binding molecule |
| US20120263715A1 (en) | 2009-10-28 | 2012-10-18 | Medimmune, Llc | Topical Methods Of Treating RSV Infections And Related Conditions |
| EP2591000B1 (en) * | 2010-07-09 | 2017-05-17 | Janssen Vaccines & Prevention B.V. | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
| AU2013234046B2 (en) * | 2012-03-16 | 2017-09-07 | University Health Network | Methods and compositions for modulating Toso activity |
| US20150158942A1 (en) * | 2012-05-22 | 2015-06-11 | Shire Human Genetic Therapies, Inc. | Anti-ccl2 antibodies for treatment of scleroderma |
| RS60056B1 (sr) | 2013-02-01 | 2020-04-30 | Medimmune Llc | Epitopi f proteina respiratornog sincicijalnog virusa |
| RS60387B1 (sr) | 2014-01-15 | 2020-07-31 | Medimmune Llc | Rsv-specifična antitela i njihovi funkcionalni delovi |
| JP2020509025A (ja) | 2017-03-01 | 2020-03-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | モノクローナル抗体製剤 |
| TWI911431B (zh) | 2017-03-01 | 2026-01-11 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
-
2015
- 2015-01-14 RS RS20200640A patent/RS60387B1/sr unknown
- 2015-01-14 KR KR1020167020393A patent/KR102188437B1/ko active Active
- 2015-01-14 ES ES15737068T patent/ES2795727T3/es active Active
- 2015-01-14 SI SI201531183T patent/SI3094353T1/sl unknown
- 2015-01-14 EP EP15737068.5A patent/EP3094353B1/en active Active
- 2015-01-14 AU AU2015206570A patent/AU2015206570A1/en not_active Abandoned
- 2015-01-14 PL PL15737068T patent/PL3094353T3/pl unknown
- 2015-01-14 PT PT157370685T patent/PT3094353T/pt unknown
- 2015-01-14 SM SM20200282T patent/SMT202000282T1/it unknown
- 2015-01-14 WO PCT/US2015/011391 patent/WO2015108967A2/en not_active Ceased
- 2015-01-14 US US15/111,610 patent/US20160340414A1/en not_active Abandoned
- 2015-01-14 JP JP2016541720A patent/JP6836398B2/ja active Active
- 2015-01-14 HU HUE15737068A patent/HUE048855T2/hu unknown
- 2015-01-14 EP EP23215838.6A patent/EP4353316A3/en active Pending
- 2015-01-14 CA CA2933200A patent/CA2933200C/en active Active
- 2015-01-14 MX MX2016008639A patent/MX374517B/es active IP Right Grant
- 2015-01-14 LT LTEP15737068.5T patent/LT3094353T/lt unknown
- 2015-01-14 EP EP20161884.0A patent/EP3741390A1/en not_active Withdrawn
- 2015-01-14 HR HRP20200607TT patent/HRP20200607T1/hr unknown
- 2015-01-14 CN CN202211184987.8A patent/CN116355080A/zh active Pending
- 2015-01-14 DK DK15737068.5T patent/DK3094353T3/da active
- 2015-01-14 CN CN201580003410.4A patent/CN105916520A/zh active Pending
- 2015-01-15 TW TW104101373A patent/TWI705974B/zh active
-
2018
- 2018-06-08 US US16/003,455 patent/US10689437B2/en active Active
-
2020
- 2020-02-10 JP JP2020020602A patent/JP2020103293A/ja active Pending
- 2020-05-01 US US16/864,454 patent/US11186628B2/en active Active
- 2020-06-05 CY CY20201100509T patent/CY1123425T1/el unknown
- 2020-06-10 AU AU2020203831A patent/AU2020203831A1/en not_active Abandoned
-
2021
- 2021-06-25 AU AU2021204339A patent/AU2021204339B2/en active Active
- 2021-10-22 US US17/451,955 patent/US11661449B2/en active Active
-
2023
- 2023-01-27 JP JP2023010903A patent/JP2023052693A/ja active Pending
- 2023-04-18 US US18/302,400 patent/US12173050B2/en active Active
- 2023-04-25 CY CY2023011C patent/CY2023011I2/el unknown
- 2023-04-25 FR FR23C1016C patent/FR23C1016I2/fr active Active
- 2023-04-25 NO NO2023016C patent/NO2023016I1/no unknown
- 2023-04-26 FI FIC20230016C patent/FIC20230016I1/fi unknown
- 2023-04-26 NL NL301228C patent/NL301228I2/nl unknown
- 2023-04-27 LU LU00305C patent/LUC00305I2/fr unknown
- 2023-04-28 LT LTPA2023514C patent/LTC3094353I2/lt unknown
- 2023-05-02 HU HUS2300019C patent/HUS2300019I1/hu unknown
-
2024
- 2024-11-11 US US18/943,007 patent/US20250179153A1/en active Pending
-
2025
- 2025-02-14 AU AU2025201056A patent/AU2025201056A1/en active Pending